Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Washington University School of Medicine
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00455403CT.gov Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prediabetes Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Chloroquine (this asset) | Washington University School of Medicine | P2 | CCC · 52 |
| Metformin | Yu Chen | P4 | A |
| Liraglutide | Woman's | P4 | BBB |
| Semaglutide | Esbjerg Hospital - University Hospital of Southern Denmark | P4 | BBB |
| Exenatide | RenJi Hospital | P4 | BBB |
| Empagliflozin | The University of Texas Health Science Center at San Antonio | P4 | BBB |
| Sitagliptin | Vanderbilt University Medical Center | P4 | BB |
| Pioglitazone | VA Office of Research and Development | P4 | BB |
| Avexitide | Vanderbilt University Medical Center | P4 | BB |
+42 more in the Prediabetes Syndrome cohort
Other indications for Chloroquine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glioblastoma | — | P3 | B · 58 |
| Abdominal Obesity-Metabolic Syndrome | — | P2 | CCC · 52 |
| Inherited Lipid Metabolism Disorder | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Chloroquine in Prediabetes Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/chloroquine-prediabetes-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →